KRAS and colorectal carcinoma: That being said, we believe that in clinical practice, healthcare providers should carefully assess the thrombotic risk in CRC patients, taking into account various factors, including genetic mutations like KRAS, to provide appropriate prophylactic or therapeutic interventions when necessary.